Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition

Pediatric Blood and Cancer

Volumn 46, Issue 5, 2006, Pages 614-623

  Hughes, Dennis P M ^a   Thomas, Dafydd G ^c   Giordano, Thomas J ^b   McDonagh, Kevin T ^d   Baker, Laurence H ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

CI 1033; EGFR; ErbB; Her 2; Her 4; Osteosarcoma; Phosphorylation; Signaling; Tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (3 MORPHOLINOPROPOXY) 6 QUINAZOLINYL]ACRYLAMIDE; PROTEIN TYROSINE KINASE;

ARTICLE; BONE TUMOR; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SARCOMA CELL; TISSUE CULTURE; TUMOR GROWTH;

APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL MEMBRANE; CELL NUCLEUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MORPHOLINES; OSTEOSARCOMA; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 33645322113     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20454     Document Type: Article

References (71)

1. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Investig 2001;19:292-315.
2. Meyer WH, Malawer MM. Osteosarcoma. Clinical features and evolving surgical and chemotherapeutic strategies. Pediatr Clin N Am 1991;38:317-348.
3. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the children's cancer group. J Clin Oncol 1997;15:76-84.
4. Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003;97:3068-3075.
5. Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001;37:32-38.
6. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2003;21:2011-2018.
7. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J Clin Oncol 2003;21:710-.
8. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: A pediatric oncology group study. J Clin Oncol 1998;16:3641-3648.
9. Bacci G, Ferrari S, Longhi A, et al. Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 2001;8:883-888.
10. Trieb K, Kotz R. Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 2001;33:11-17.
11. Dhaini HR, Thomas DG, Giordano TJ, et al. Cytochrome p450 cyp3a4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 2003;21:2481-2485.
12. Wunder JS, Bull SB, Aneliunas V, et al. Mdr1 gene expression and outcome in osteosarcoma: A prospective, multicenter study. J Clin Oncol 2000;18:2685-2018.
13. Pakos E, Ioannidis J. The association of p-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 2003;98:581-589.
14. Oda Y, Wehrmann B, Radig K, et al. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: Its correlation with proliferating activities and p53 expression. Gen Diagn Pathol 1995;141:97-103.
15. Kakar S, Mihalov M, Chachlani N, et al. Correlation of c-fos, p53, and pcna expression with treatment outcome in osteosarcoma. J Surg Oncol 2000;73:125-126.
16. Worth L, Lafleur E, Jia S, et al. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002;9:823-827.
17. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-78.
18. Gorlick R, Huvos AG, Heller G, et al. Expression of Her2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-2788.
19. Zhou H, Randall R, Brothman A, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
20. Merimsky O, Rollender Y, Issakov J, et al. Induction chemotherapy for bone sarcoma in adults: Correlation of results with erbB-4 expression. Oncol Rep 2003;10:1593-1599.
21. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of p-glycoprotein, Her-2/erbB-2, p53, and bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100:1936-1942.
22. Fellenberg J, Krauthoff A, Pollandt K, et al. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 2004;84:113-121.
23. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neuoncogene. Science 1987;235:177-182.
24. Akatsuka T, Wada T, Kokai Y, et al. Loss of erbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 2001;60:361-366.
25. Maitra A, Wanzer D, Weinberg AG, et al. Amplification of the Her-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92:677-683.
26. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of Her-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001;14:1277-1283.
27. Thomas DG, Giordano TJ, Sanders D, et al. Absence of her2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002;8:788-793.
28. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-1404.
29. Hughes DPM, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of her-4 in primary osteosarcoma. Cancer Res 2004;64:2047-2053.
30. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (herceptin) in patients with her2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83.
31. Saltz LB, Meropol NJ, Loehrer PJ, Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
32. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-3243.
33. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual erbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 2001;61:7196-7203.
34. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265-46272.
35. Hightower M. Erlotinib (osi-774, tarceva), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2003;4:336-338.
36. Gibson A. Activity of zd1839 (gefitinib, iressa) in previously treated patients with recurrent and advanced non-small-cell lung cancer. Clin Lung Cancer 2002;4:23-25.
37. Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003;21:2094-2100.
38. Anido J, Matar P, Albanell J, et al. Zd1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/Her2 and EGFR/Her3 heterodimers and prevents heregulin signaling in Her2-overexpressing breast cancer cells. Clin Cancer Res 2003;9:1274-.
39. Slichenmyer W, Elliott W, Fry D. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001;28:80-85.
40. Allen L, Lenehan P, Eiseman I, et al. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002;29:11-21.
41. Karni R, Jove R, Levitzki A. Inhibition of pp60c-src reduces bcl-xl expression and reverses the transformed phenotype of cells overexpressing EGF and Her-2 receptors. Oncogene 1999;18:4654-4662.
42. Wahl M, Nishibe S, Kim J, et al. Identification of two epidermal growth factor-sensitive tyrosine phosphorylation sites of phospholipase c-gamma in intact hsc-1 cells. J Biol Chem 1990;265:3944-3948.
43. Rojas M, Yao S, Lin Y-Z. Controlling epidermal growth factor (EGF)-stimulated ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 1996;271:27456-27461.
44. Zwick E, Hackel P, Prenzel N, et al. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 1999;20:408-412.
45. Burke P, Schooler K, Wiley HS, Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 2001;12:1897-1910.
46. Dankort D, Wang Z, Blackmore V, et al. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol 1997;17:5410-5425.
47. Kwon YK, Bhattacharyya A, Alberta JA, et al. Activation of erbB2 during wallerian degeneration of sciatic nerve. J Neurosci 1997;17:8293-8299.
48. Fry D. Mechanism of action of erbB tyrosine kinase inhibitors. Exp Cell Res 2003;284:131-139.
49. Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitylation and degradation of erbB receptor tyrosine kinases: Implications for cancer therapy. EMBO J 2002;21:2407-2417.
50. Murray E, Provvedini D, Curran D, et al. Characterization of a human osteoblastic osteosarcoma cell line (Saos-2) with high bone alkaline phosphatase activity. J Bone Miner Res 1987;2:231-238.
51. Oliner J, Kinzler K, Meltzer P, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83.
52. Dini M, Jafari K, Faiferman I. Cell-mediated cytotoxicity in preinvasive and invasive squamous cell carcinoma of the cervix. Obstet Gynecol 1980;55:728-731.
53. Soule HD, Vazquez J, Long A, et al. A human cell line from a plueral effusion derived from a breast carcinoma. J Natl Cancer Insit 1973;51:1409-1416.
54. Versteeg H, Nijhuis E, van den Brink G, et al. A new phosphospecific cell-based elisa for p42/p44 mitogen-activated protein kinase (mapk), p38 mapk, protein kinase b and camp-response-element-binding protein. Biochem J 2000;350(Pt 3): 717-722.
55. Miller C, Chen G, Gharib T, et al. Increased c-crk proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 2003;22:7950-7957.
56. Billecke C, Ljungman M, McKay B, et al. Lack of functional prb results in attenuated recovery of mrna synthesis and increased apoptosis following UV radiation in human breast cancer cells. Oncogene 2002;21:4481-4489.
57. Sasaoka T, Langlois W, Leitner J, et al. The signaling pathway coupling epidermal growth factor receptors to activation of p21 ras. J Biol Chem 1994;269:32621-32625.
58. Chang C, Lazar C, Walsh B, et al. Ligand-induced internalization of the epidermal growth factor receptor is mediated by multiple endocytic codes analogous to the tyrosine motif found in constitutively internalized receptors. J Biol Chem 1993;268:19312-19320.
59. Olayioye MA, Beuvink I, Horsch K, et al. ErbB receptor-induced activation of stat transcription factors is mediated by src tyrosine kinases. J Biol Chem 1999;274:17209-17218.
60. Rio C, Buxbaum JD, Peschon JJ, et al. Tumor necrosis factor-alpha- converting enzyme is required for cleavage of erbB4/Her4. J Biol Chem 2000;275:10379-10387.
61. Ni C-Y, Murphy MP, Golde TE, et al. Gamma-secretase cleavage and nuclear localization of erbB-4 receptor tyrosine kinase. Science 2001;294:2179-2181.
62. Lee H-J, Jung K-M, Huang YZ, et al. Presenilin-dependent gamma-secretase-like intramembrane cleavage of erbB4. J Biol Chem 2002;277:6318-6323.
63. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-1655.
64. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-5287.
65. Wiley H. Trafficking of the erbB receptors and its influence on signaling. Exp Cell Res 2003;284:78-88.
66. Kurpad S, Zhao X, Wikstrand C, et al. Tumor antigens in astrocytic gliomas. Glia 1995;15:244-256.
67. Batra S, Castelino-Prabhu S, Wikstrand C, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRviii gene. Cell Growth Differ 1995;6:1251-.
68. Moscatello D, Montgomery R, Sundareshan P, et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996;13:85-96.
69. Moscatello DK, Holgado-Madruga M, Emlet DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998;273:200-5729.
70. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-142.
71. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.